FDA approves nivolumab for adjuvant Stage IIB/C melanoma treatment
Opdivo is now approved for patients 12 and older with completely resected Stage IIB/C melanoma; a separate record lists a subcutaneous nivolumab-hyaluronidase approval with no details given.
On October 13, 2023, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older.1
A second FDA record, titled "FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection,"2 indicates that a subcutaneous formulation combining nivolumab with hyaluronidase-nvhy has also received approval. The source material does not specify an approval date, indication, dosing, or any other details for this subcutaneous product.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.